exemestane sold brand name aromasin among others medication used treat breast cancer member class antiestrogens known aromatase inhibitors breast cancers require estrogen grow cancers estrogen receptors ers called erpositive may also called estrogenresponsive hormonallyresponsive hormonereceptorpositive aromatase enzyme synthesizes estrogen aromatase inhibitors block synthesis estrogen lowers estrogen level slows growth cancers exemestane indicated adjuvant treatment postmenopausal women estrogenreceptor positive early breast cancer received two three years tamoxifen switched completion total five consecutive years adjuvant hormonal us fda approval october exemestane also indicated treatment advanced breast cancer postmenopausal women whose disease progressed following tamoxifen premenopausal women breast cancer adjuvant treatment ovarian suppression plus aromatase inhibitor exemestane compared ovarian suppression plus tamoxifen provides new treatment option reduces risk recurrence text soft trials demonstrated improved disease free survival patients treated exemestane ovarian suppression compared tamoxifen ovarian suppression group premenopausal women receive ovarian suppression may benefit aromatase inhibitor class drugs recommended postmenopausal drug contraindicated premenopausal women course includes pregnant lactating common side effects patients hot flashes sweating typical estrogen deficiency caused exemestane also insomnia headache joint pain nausea fatigue mainly observed patients advanced breast occasional decrease lymphocytes observed approximately patients receiving aromasin particularly patients preexisting exemestane androgenic properties similarly formestane produce androgenic side effects acne weight gain although generally associated supratherapeutic dosages single doses least mg well continuous therapy mg usual daily dose well tolerated lifethreatening overdosing known humans animal studies doses adjusted body surface exemestane metabolized liver enzyme inhibitor ketoconazole significant effect exemestane levels clinical trial strong inductor rifampicin significantly cut exemenstane levels half auc cmax single dose potentially compromising effectiveness inductors carbamazepine st johns wort expected similar clinical relevance effect estrogens probably reduce exemestane would usually counterproductive reduce bodys estrogen synthesis exemestane substitute estrogen pharmaceuticals exemestane oral steroidal aromatase inhibitor used erpositive breast cancer addition surgery andor radiation postmenopausal women main source estrogen ovaries premenopausal women postmenopausal women bodys estrogen produced via conversion androgens estrogen aromatase enzyme peripheral tissues ie adipose tissue like breast number sites brain estrogen produced locally via actions aromatase enzyme peripheral tissues acts locally circulating estrogen postmenopausal women well men result estrogen escaping local metabolism entering circulatory exemestane irreversible steroidal aromatase inactivator type structurally related natural substrate acts false substrate aromatase enzyme processed intermediate binds irreversibly active site enzyme causing inactivation effect also known suicide inhibition structurally similar enzyme targets exemestane permanently binds enzymes preventing converting androgen type ii aromatase inhibitors anastrozole letrozole contrast steroids work interfering aromatases study conducted young adult males found estrogen suppression rate exemestane varied estradiol estrone exemestane quickly absorbed gut undergoes strong firstpass effect liver highest blood plasma concentrations reached hours breast cancer patients hours healthy subjects maximal aromatase inhibition occurs two three absorbed substance bound plasma proteins liver enzyme oxidizes methylidene group position group fivemembered ring reduced aldoketo reductases alcohol resulting metabolites excreted via urine via feces within week original substance accounts excretion urine terminal halflife exemestane known chemically like aromatase inhibitors formestane atamestane exemestane steroid structurally similar natural substrate aromatase distinguished natural substance methylidene group position additional double bond position pure exemestane white offwhite powder soluble dmso least mgml optical rotation Î±d per decimetre nm exemestane used doping raise luteinizing hormone lh follicle stimulating hormone fsh levels turn increases ratio male female sexual hormones improves performance drug also counteracts gynecomastia well fat water retention following excessive aromatase production due testosterone along aromatase inhibitors exemestane world antidoping agencys list prohibited oral exemestane mgday years adjuvant therapy generally effective years continuous adjuvant tamoxifen treatment postmenopausal women earlystage estrogen receptorpositiveunknown receptor status breast large welldesignedcitation needed trial preliminary data openlabel team trial comparing exemestane tamoxifen indicated exemestane mgday also effective primary adjuvant treatment earlystage breast cancer postmenopausal interim phase iii trial results showed adding everolimus exemestane therapy advanced breast cancer significantly improve progressionfree survival compared exemestane therapy phase iii trial reported concluding use exemestane postmenopausal women increased risk breast cancer reduced incidence invasive breast cancer women months administration exemestane dose mgday resulted reduction risk breast cancer compared placebo annual incidence rates respectively hazard ratio ci p httpsenwikipediaorgwikiexemestane